Results 201 to 210 of about 184,127 (310)

Angiotensin-converting enzyme inhibitors will help in improving stroke outcome if given immediately after stroke

, 2010
M.V. Padma
openalex   +1 more source

The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults With Human Immunodeficiency Virus Infection [PDF]

, 2017
Kristine M. Erlandson, Douglas Kitch, C. William Wester, Robert C. Kalayjian, Edgar T. Overton, José Castillo‐Mancilla, Susan L. Koletar, Constance A. Benson, Thomas Campbell, Kevin Robertson, Judith J. Lok   +10 more
openalex   +1 more source

The emerging role of Nrf2 in heart failure: From cardioprotection to therapeutic approaches

ESC Heart Failure, EarlyView.
Nrf2 signalling is impaired in heart failure, contributing to oxidative stress, mitochondrial dysfunction, and ferroptosis, which drive neurohormonal activation, inflammation, and ischaemia‐reperfusion injury. This loss of Nrf2 activity exacerbates hypertension, diabetic cardiomyopathy, and cardiotoxicity, accelerating progression to overt heart ...
Emiliano Fiori, Sergio Davinelli, Armando Ferrera, Alessandro Medoro, Carlo Barsali, Allegra Battistoni, Maurizio Volterrani, Massimo Volpe, Luciano Saso, Speranza Rubattu   +9 more
wiley   +1 more source

Comparative Risk Assessment in Hypertensive Patients With Metabolic Syndrome by Exploring Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. [PDF]

Cureus
Khan MH, Pathan S, Ansari K, Baig S, Ghafoor A, Minhas M, Saleem K.   +6 more
europepmc   +1 more source

A novel treatment score (QUAD score) to promote treatment optimization in heart failure with a reduced ejection fraction

ESC Heart Failure, EarlyView.
The QUAD score was developed to promote adherence to clinical practice guidelines for patients with heart failure and a reduced left ventricular ejection fraction <50%. In newly diagnosed patients who had completed therapy titration, we found that patients with an excellent QUAD score had a significant reduction in the risk of mortality or ...
Henry Oluwasefunmi Savage, Jason N. Dungu, Anthony Dimarco, Brian Li, Samantha Langley, Jonathan Kojo Amoah, Paraic Cliffe, Archana Ganapathy, Peter Watters, Patricia Campbell, Nicola Melarkey, Simon Duckett, Sean Davies, Matthew Dewhurst, Karen Hann, Louise Clayton, Rhys Williams, Victoria Ruszala, Teresa Onwere‐Tan, Fozia Zahir Ahmed, Ibrahim Arosi, Kimberly Gray, Mark C. Petrie, John G.F. Cleland   +23 more
wiley   +1 more source

COVID-19 Pandemic Waves and 2024-2025 Winter Season in Relation to Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers and Amantadine. [PDF]

Healthcare (Basel)
Puigdellívol-Sánchez A, Juanes-González M, Calderón-Valdiviezo AI, Losa-Puig H, González-Salvador M, León-Pérez M, Pueyo-Antón L, Franco-Romero M, Lozano-Paz C, Cortés-Borra A, Valls-Foix R.   +10 more
europepmc   +1 more source

SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

ESC Heart Failure, EarlyView.
Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra, Daniela Tomasoni, Marianna Adamo, Offer Amir, Stefan D. Anker, Antoni Bayes‐Genis, Michael Boehm, Javed Butler, Ovidiu Chioncel, Gerasimos Filippatos, Finn Gustafsson, Ewa A. Jankowska, Juan Carlos Kaski, Brenda Moura, Mark C. Petrie, Piotr Ponikowski, Amina Rakisheva, Arsen Ristic, Francois Roubille, Gianluigi Savarese, Petar Seferovic, Peter van der Meer, Maurizio Volterrani, Andrew J. Coats, Vijay K. Chopra, Giuseppe Rosano   +25 more
wiley   +1 more source

Whole Exome Sequencing in Drug-Induced Angioedema Caused by Angiotensin-Converting Enzyme Inhibitors: A Pilot Study in Five Patients. [PDF]

J Clin Med
Mendoza-Alvarez A, Martinez-Tadeo JA, Perez-Rodríguez E, Barrios-Recio J, García-Robaina JC, Corrales A, Marcelino-Rodríguez I, Lorenzo-Salazar JM, González-Montelongo R, Flores C, Callero A.   +10 more
europepmc   +1 more source

Over diagnosis of bradykinin angioedema in patients treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. [PDF]

World Allergy Organ J, 2023
Douillard M, Deheb Z, Bozon A, Raison-Peyron N, Dereure O, Moulis L, Soria A, Du-Thanh A.   +7 more
europepmc   +1 more source

Re‐PERFUSE: Phase 1b study of AZD3427, a novel relaxin receptor agonist, on renal perfusion in HFrEF patients

ESC Heart Failure, EarlyView.
Abstract Aims Renal impairment frequently coexists with heart failure (HF) and is associated with increased risk of poor clinical outcomes. This highlights the urgent need for therapies targeting both cardiac and renal dysfunction. AZD3427, a long‐acting recombinant fusion protein and relaxin analogue that selectively activates the relaxin family ...
Marcin Ufnal, Macarena P. Quintana‐Hayashi, Kathleen Connolly, Daniel Pettersen, Zsolt Cselényi, Aurelija Jucaite, Magnus Schou, Andrea Varrone, Melanie Chan, Lars H. Lund   +9 more
wiley   +1 more source